Objective: To assess the cognitive phenotype of glucocerebrosidase (GBA) mutation carriers with early-onset Parkinson disease (PD).
noncarriers on the Montreal Cognitive Assessment (MoCA). 11 In addition, a mouse model of Gaucher disease was shown to exhibit memory deficits as well as progressive accumulation of ␣-synuclein/ubiquitin aggregates in hippocampal neurons. 12 In the current study, our primary goal was to examine the neuropsychological profile of GBA carriers compared to noncarriers. To further characterize the GBA phenotype, we assessed extrapyramidal features, olfaction, and depression. METHODS Participants. A total of 147 individuals with early-onset PD (33 GBA carriers and 114 noncarriers) who participated in Part II of the CORE-PD study were included. Details of the CORE-PD study have been described. 13 In brief, patients with PD, diagnosed by movement disorders specialists, were recruited for Part I of CORE-PD from 16 sites based on AAO of PD Ͻ51 years and a score on the MMSE Ͼ23. (The inclusion of individuals with MMSE Ͼ23 was incorporated to ensure that a reliable history could be obtained from each subject. There was no MMSE exclusion criterion for the follow-up, Part II examination.) A blood sample for DNA was sent to the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org). Participants were screened for mutations in SNCA, PARKIN, PINK-1, DJ-1, LRRK2, and GBA (N370S and L444P mutations). 6 Given the higher frequency of GBA mutations among Ashkenazi Jews, participants who selfreported Ashkenazi Jewish ancestry were further screened for an additional 6 common GBA mutations (V394L, D409G, A456P, R496H, 84GG, and exon 2 IVS2 ϩ 1) by direct sequencing. A total of 147 participants completed the Part II evaluation. The present analysis was restricted to 33 carriers of GBA mutations and 60 individuals who did not have any mutations in the other genes tested. 14 The GBA mutation carriers (n ϭ 33) included 7 heterozygous L444P carriers, 16 heterozygous N370S carriers, 1 N370S homozygote, 2 84GG carriers, and 1 R496H carrier. Six individuals were heterozygous for GBA mutations and carried mutations in other PD-related genes (3 with both GBA and PARKIN mutations, 3 with both GBA and LRRK2 G2019S mutations). The analyses presented here focused on the 26 heterozygous GBA mutation carriers who did not have PARKIN or LRRK2 mutations. We also conducted sensitivity analyses including all 33 GBA carriers.
To ensure that the noncarriers were frequency matched to the GBA carriers in age and PD duration at the time of the examination, we included only noncarriers who were 47 years or older with PD duration between 7 and 25 years, similar to GBA carriers. This resulted in the exclusion of 21 noncarriers. The final number of included participants was 72 (33 GBA carriers, 39 noncarriers).
Clinical evaluation.
Clinical evaluation in Part II of CORE-PD included a neurologic examination performed by a research physician, a videotaped assessment of the Unified Parkinson's Disease Rating Scale (UPDRS) evaluated by a movement disorders specialist (E.D.L.), a neuropsychological battery, and a psychiatric evaluation including the Beck Depression Inventory-II (BDI-II). 15 The University of Pennsylvania Smell Identification Test (UPSIT, Sensonics, Inc., Haddonfield, NJ) 16 was added in 2008 and was available for 31 participants. A Clinical Dementia Rating (CDR) 17 score was assigned to each participant by a research physician (L.R.) who administered the neurologic and neuropsychological testing. A consensus panel, including the research physician (L.R.), a neurologist (K.M.), and a neuropsychologist (E.C.), assigned a clinical consensus diagnosis to each participant based on medical history, neurologic examination, neuropsychological performance, and functional impairment. Dementia diagnosis required impairment on neuropsychological evaluation in at least 2 of the following domains: memory, language, executive function, and visuospatial processing, as well as functional impairment as reflected by a CDR score greater than 0. Mild cognitive impairment (MCI) was diagnosed using Petersen's criteria, i.e., impairment in at least 1 neuropsychological domain or low scores in more than 1 domain, with no significant functional impairment. 18 None of the researchers was aware of the participants' mutation status at the time of the evaluation or consensus diagnosis.
Standard protocol approvals, registrations, and patient consents.
Institutional review boards at all participating sites approved the protocols and consent procedures. Written informed consent was obtained from all participants in the study.
Neuropsychological evaluation. Details of the neuropsychological battery have been previously described 14 and are summarized in table e-1 on the Neurology Web site at www.neurology.org. The battery was designed so that it was time-limited (i.e., with an administration time of approximately 30 -45 minutes), could be administered in participants' homes, could be administered in English and Spanish, and could be successfully completed by patients with motor impairment. A second MMSE was performed on all participants at the time of the neuropsychological battery but was not included in the domain scores. Five cognitive domains were created based on previous research assessing predictors of cognitive decline in PD (table e-1) . 14,19 -20 In a separate analysis, we further reclassified the battery into 3 domains (table e-2): executive function (including executive function, processing speed, and attention), memory (including memory tests as in table e-1 and California Verbal Learning Test-II recognition errors), and visuospatial domain (unchanged).
Statistical analysis.
Demographic data, disease characteristics, MMSE, neuropsychological test performance, and UPSIT performance of GBA carriers and noncarriers were compared using 2 , Fisher exact, and Student t tests, as appropriate. Individual neuropsychological test scores for all participants were transformed to create Z scores using means and standard deviations of all participants. Composite scores for each domain were computed by averaging the mean Z scores from the individual tests comprising each domain (see table e-1). Performance on neuropsychological testing was compared between GBA mutation carriers and noncarriers on individual tests and cognitive domains.
CDR scores were categorized as 0 (normal), 0.5, or 1 or higher (dementia) and compared between GBA carriers and noncarriers. The association between clinical diagnosis of cognitive impairment (which was made by consensus meeting based on neuropsychological performance and CDR), either MCI or dementia (dependent variable), and GBA mutation status (independent variable) was assessed in logistic regression models. The association was first assessed in a univariate model, and then in a multivariate model, adjusting for age in years, AAO of PD, gen-der, UPDRS-III score, motor phenotype (tremor dominant vs postural instability gait difficulty), 21 and years of education.
Finally, sensitivity analyses were performed. We repeated the analyses, including all GBA mutation carriers (n ϭ 33), and all noncarriers (n ϭ 60), including those (n ϭ 21) who were excluded for age and disease duration frequency matching.
RESULTS
Demographic and disease characteristics of carriers and noncarriers of GBA mutations are presented in table 1. Age (frequency matched), gender, education, AAO, and BDI-II scores did not differ between carriers and noncarriers. UPSIT performance was in the severe microsmia range (score of 25 or less out of 40) 16 MMSE scores, cognitive domain scores, CDR scores, and the clinical consensus diagnoses of cognitive impairment are reported in table 3. GBA carriers' MMSE performance was significantly lower than that of noncarriers. Mean scores in all 5 cognitive domains were lower in the GBA carrier group, reaching significance for the memory ( p ϭ 0.017) and visuospatial ( p ϭ 0.028) domains. These findings were unchanged when the neuropsychological battery was reclassified into 3 domains (memory, p ϭ 0.015; executive function, p ϭ 0.394; visuospatial, p ϭ 0.028). GBA carriers were more likely to receive higher CDR scores than noncarriers ( p Ͻ 0.001).
Among participants who received a consensus clinical diagnosis of dementia (11 GBA carriers, 6 noncarriers), GBA mutation carriers did not present a distinctive pattern of impairment in specific cognitive domains. All participants with dementia had both memory and executive impairment. GBA mutation carriers were more likely to receive a clinical consensus diagnosis of MCI or dementia than noncarriers ( p ϭ 0.004, table 3). In a univariate logistic model, GBA mutation status was associated with clinical diagnosis of cognitive impairment (either MCI or dementia combined) (odds ratio [OR] ϭ 5.8, 95% confidence interval [CI] 1.7-19.9, p ϭ 0.005). The association persisted when adjusted for age, gender, disease duration, UPDRS-III, motor phenotype, and education (OR ϭ 6.2, 95% CI 1.3-29.0, p ϭ 0.021).
Sensitivity analyses including all GBA carriers (n ϭ 33) and all noncarriers (n ϭ 60) revealed that GBA carriers were more impaired on memory ( p ϭ 0.046) and attention ( p ϭ 0.007) domains compared to noncarriers, using the 5-domain model. In this larger sample, significant differences between GBA carriers vs noncarriers in CDR scores ( p Ͻ 0.001) and in the association between GBA mutation status and cognitive impairment ( p ϭ 0.001) were similar to those obtained in the primary analyses. DISCUSSION While longitudinal follow-up of patients with PD suggests that cognitive impairment occurs in 83% of patients with PD followed up to 20 years, 22 studies have shown marked heterogeneity in the profile of cognitive impairment and in the time from onset of motor symptoms to the development of cognitive impairment. [23] [24] [25] Previous studies have shown that genetic risk factors, including variations in microtubule-associated protein tau (MAPT), 26 ␣-synuclein (SNCA), 26 and catechol-O-methyltransferase (COMT) 27, 28 may explain some of the heterogeneity in cognitive performance in PD. We and others have shown that GBA mutations are associated with cortical Lewy body pathology. GBA mutation status was also previously associated with dementia using DSM-IV criteria, after adjusting for covariates, including APOE4 status and Alzheimer disease pathology. 7 Our findings of olfactory and cognitive impairment, most notably in nonverbal memory tasks, are all consistent with diffuse cortical neuropathol-ogy. The association between GBA mutation status and other nonmotor signs and symptoms of PD (e.g., REM sleep behavior disorder or hallucinations) remains to be investigated. We may have underestimated differences in cognitive performance. Our study was probably biased toward the null: first, we compared GBA carriers to other affected individuals who by themselves exhibit cognitive impairment (table 2) . Second, we included only participants with MMSE Ͼ23 on initial evaluation. We cannot conclude whether GBA mutation status is associated with PD dementia only or with dementia with Lewy body as well. Finally, because only selected mutations were genotyped, rather than complete sequencing, we may have inadvertently misclassified other GBA mutation carriers as noncarriers.
While GBA mutation status may explain a portion of the variability in cognitive performance, not all GBA carriers demonstrate cognitive impairment. For example, one of the GBA mutation carriers whose performance on neuropsychological testing was within normal range (table 3) had a motor disease duration of 21 years. Further research is required to understand additional modifiers of cognitive performance, some of which may be protective. Our study was not powered to assess for interactions with MAPT, SNCA, or COMT variants, or to assess for a "dose" effect. It included only a single carrier of 2 GBA mutations, who was excluded from all but the sensitivity analyses. It also was not powered to compare carriers of different GBA mutations, e.g., N370S and R496H vs L444P and 84GG. A previous study has reported that carriers of "severe" GBA mutations (including L444P) may have a higher risk for PD than carriers of "milder" mutations (e.g., N370); however, cognitive impairment was not assessed. 29 The neuropsychological battery, which was limited in scope, may have lacked tests that would have identified more specific executive deficits (e.g., Wisconsin Card Sorting Test). Finally, the study design, which includes a single complete neuropsychological evaluation that did not allow us to assess rate of progression, also represents a limitation.
Further research is required to assess whether nonverbal memory may be used as an early marker of cognitive impairment in mutation carriers. GBA mutation carriers may serve as an enriched sample to assess for early cognitive outcomes. Prospective longitudinal studies which include GBA mutation carriers with and without PD will help assess the time and rate of development of cognitive impairment in carriers. 
